Pharming Group N.V. presents its (unaudited) financial report for the nine months and third quarter ended 30 September 2020.

Pharming Group N.V. presents its (unaudited) financial report for the six months ended 30 June 2020.

Pharming Group N.V. announces that at its Annual General Meeting of shareholders (AGM), held today, the proposals related to remuneration were withdrawn and all other proposals were approved.

Pharming Group N.V. presents its (unaudited) financial report for the first quarter of the year ended 31 March 2020.

Pharming Group N.V. invites its shareholders to the 2020 Annual General Meeting (AGM) to be held at 14:00 CET on 20 May 2020

Annual Report 2019 is available for download on the Pharming website today

Pharming Group N.V. announces that it has been included in the Euronext Amsterdam Midkap index (AMX).

The Company will hold a conference call at 13.00 CET/07.00 EST today. Dial in details can be found on page 12 of the press release.

Pharming Group N.V. announces today the placement of €125 million of senior unsecured convertible bonds due 2025 (the “Bonds”). The offer was fully subscribed. The Bonds were offered via an accelerated book building process through a private placement only to institutional investors outside the United States of America, Australia, South Africa, and Japan.

Pharming Group N.V. today announces the launch of an offering (the “Offering”) of approximately €125 million of senior unsecured convertible bonds due 2025 (the “Bonds”). The net proceeds of the issue of the Bonds will be used to redeem the approximately US$ 56 million loan with Orbimed Advisors in full, thereby reducing the Company’s financing costs and extending its debt maturity through the period to approval of most of the Company’s existing pipeline. The balance of the net proceeds will be used to support capital expenditure in relation to the expansion of the commercialization and manufacturing infrastructure of the Company, and serve as funding for the launch of Pharming’s recently acquired leniolisib product and for additional acquisitions/in-licensing opportunities.